Roche: new Esbriet tablet formulation approved in Europe.
(CercleFinance.com) - Roche's new Esbriet tablet formulation has been approved in Europe for mild-to-moderate idiopathic pulmonary fibrosis, the Swiss drugmaker said on Tuesday.
The new tablets offer people a maintenance option with fewer pills per day: patients can take one tablet three times per day instead of three capsules three times per day, the company said.
Idiopathic pulmonary fibrosis is a fatal condition that causes irreversible, progressive scarring of the lungs. Half of people fail to survive for more than three years following diagnosis.
Copyright (c) 2017 CercleFinance.com. All rights reserved.
The new tablets offer people a maintenance option with fewer pills per day: patients can take one tablet three times per day instead of three capsules three times per day, the company said.
Idiopathic pulmonary fibrosis is a fatal condition that causes irreversible, progressive scarring of the lungs. Half of people fail to survive for more than three years following diagnosis.
Copyright (c) 2017 CercleFinance.com. All rights reserved.